KFGO3h
US FDA approves IntraBio’s drug for rare genetic disease
The U.S. Food and Drug Administration approved IntraBio's drug for a rare and fatal genetic disorder, the health regulator ...
Zevra Therapeutics prices rare genetic disorder drug at up to $106,000 per month
Zevra Therapeutics' drug, Miplyffa, for treating a rare and fatal genetic disorder will have a wholesale acquisition cost ...
GlobalData on MSN1d
EMA CHMP recommends MSD’s KEYTRUDA for gynaecological cancers
Committee for Medicinal Products for Human Use (CHMP) has recommended approval of MSD’s KEYTRUDA for two gynaecological ...
Immutep (ASX:IMM) announces positive results in head and neck cancer treatment
Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses the company's latest results in head and neck cancer.
Cure Today4d
Keytruda Improves Disease-Free Survival in Some With Urothelial Carcinoma
Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived ...
STAT4d
FDA approves first drug for rare neuron disease, Niemann-Pick type C
Parents pushed for years for treatments for the neuron disease Niemann-Pick type C. After setbacks, one drug now has FDA ...
BioPharma Dive4d
Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian
Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising ...
Keytruda beaten by Summit’s bispecific in NSCLC
The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.
ThePrint4d
This experimental lung cancer drug outperforms blockbuster medicine Keytruda. But there’s a catch
In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.
Korean Biotech’s Shares Quadruple In Seven Months, Becomes Kosdaq’s Biggest Stock
Alteogen overtakes EcoPro BM, South Korea’s largest producer of cathodes for EV batteries, to become the biggest company on the Kosdaq by market capitalization.
GlobalData on MSN5d
FDA approves MSD’s KEYTRUDA as first-line MPM treatment
The approval for the KEYTRUDA regimen is supported by results from the Phase II/III IND.227/KEYNOTE-483 trial.
Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer
Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult ...